Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| ABMR | Antibody-mediated rejection |
| ADCC | Antibody-dependent cell-mediated cytotoxicity |
| AHFS | American Hospital Formulary Service |
| AM | Acceptable mismatch |
| AMR | Antibody-mediated rejection |
| ATC | Anatomical Therapeutic Chemical classification |
| BLA | Biologics License Application |
| CAV | Clinical added value |
| CDC | Complement-dependent cytotoxicity |
| CI | Confidence interval |
| CKD | Chronic kidney disease |
| cPRA/CPRA | Calculated panel-reactive antibody |
| DSA | Donor-specific antibody |
| eGFR | Estimated glomerular filtration rate |
| EMA | European Medicines Agency |
| ESRD | End-stage renal disease |
| EU | European Union |
| F(ab′)2 | Bivalent antigen-binding antibody fragment |
| Fc | Fragment crystallizable region of an antibody |
| FDA | Food and Drug Administration |
| HLA | Human leukocyte antigen |
| HRQoL | Health-related quality of life |
| HSE | Health Service Executive |
| ICER | Incremental cost-effectiveness ratio |
| IdeS | Immunoglobulin G-degrading enzyme of Streptococcus pyogenes |
| IFE | Immunofixation electrophoresis |
| IgG | Immunoglobulin G |
| ISE | Immunosubtraction electrophoresis |
| ITT | Intention to treat |
| IV | Intravenous |
| IVIG/IVIg | Intravenous immunoglobulin |
| KAS | Kidney Allocation System |
| KEP | Kidney exchange program |
| LDKT | Living donor kidney transplantation |
| MENA | Middle East and North Africa |
| MFI | Mean fluorescence intensity |
| MICA | Major histocompatibility complex class I chain-related protein A |
| NCPE | National Centre for Pharmacoeconomics |
| NCT | ClinicalTrials.gov study identifier prefix |
| NHS | National Health Service |
| NK | Natural killer |
| PAES | Post-authorization efficacy study |
| PAS | Patient Access Scheme |
| PDUFA | Prescription Drug User Fee Act |
| PEX/PLEX | Plasma exchange |
| PRA | Panel-reactive antibody |
| QALY | Quality-adjusted life-year |
| rATG | Rabbit anti-thymocyte globulin |
| RMP | Risk management plan |
| SAB | Single-antigen bead |
| ScIgG | Single-cleaved immunoglobulin G |
| SmPC | Summary of Product Characteristics |
| SoC | Standard of care |
| SPE | Serum protein electrophoresis |
| TEAE | Treatment-emergent adverse event |
| TR | Transplant rate |
| TTP | Thrombotic thrombocytopenic purpura |
| VAT | Value-added tax |